CA1215992A - Carboxylic acid amide compounds and their derivatives - Google Patents
Carboxylic acid amide compounds and their derivativesInfo
- Publication number
- CA1215992A CA1215992A CA000456279A CA456279A CA1215992A CA 1215992 A CA1215992 A CA 1215992A CA 000456279 A CA000456279 A CA 000456279A CA 456279 A CA456279 A CA 456279A CA 1215992 A CA1215992 A CA 1215992A
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- formula
- carboxylic acid
- group
- cyclohexene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 54
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical class C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 5
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 5
- -1 aniline compound Chemical class 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 20
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 21
- 239000000126 substance Substances 0.000 claims 8
- 150000001735 carboxylic acids Chemical class 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 3
- CDIDGWDGQGVCIB-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CDIDGWDGQGVCIB-UHFFFAOYSA-N 0.000 claims 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims 2
- 230000018044 dehydration Effects 0.000 claims 2
- 238000006297 dehydration reaction Methods 0.000 claims 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 2
- RKHBXKQTJHREJG-UHFFFAOYSA-N 3,4-dimethylcyclohex-3-ene-1-carboxylic acid Chemical compound CC1=C(C)CC(C(O)=O)CC1 RKHBXKQTJHREJG-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 206010010774 Constipation Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 239000004129 EU approved improving agent Substances 0.000 abstract description 2
- 208000012902 Nervous system disease Diseases 0.000 abstract description 2
- 206010029333 Neurosis Diseases 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 208000015238 neurotic disease Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 16
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 101150085091 lat-2 gene Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000004899 motility Effects 0.000 description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- NMEZJSDUZQOPFE-UHFFFAOYSA-N Cyclohex-1-enecarboxylic acid Chemical compound OC(=O)C1=CCCCC1 NMEZJSDUZQOPFE-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- VUSWCWPCANWBFG-UHFFFAOYSA-N cyclohex-3-ene-1-carboxylic acid Chemical compound OC(=O)C1CCC=CC1 VUSWCWPCANWBFG-UHFFFAOYSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- FSWCCQWDVGZMRD-UHFFFAOYSA-N 4-methylcyclohexene Chemical compound CC1CCC=CC1 FSWCCQWDVGZMRD-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000000068 chlorophenyl group Chemical group 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- TXNWMICHNKMOBR-UHFFFAOYSA-N 1,2-dimethylcyclohexene Chemical compound CC1=C(C)CCCC1 TXNWMICHNKMOBR-UHFFFAOYSA-N 0.000 description 1
- CTMHWPIWNRWQEG-UHFFFAOYSA-N 1-methylcyclohexene Chemical compound CC1=CCCCC1 CTMHWPIWNRWQEG-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- JQQZTPKKHFAWJO-UHFFFAOYSA-N 3-methyl-1-[(4-methylphenyl)carbamoyl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1(=CC=C(C=C1)NC(=O)C1(CC(=CCC1)C)C(=O)O)C JQQZTPKKHFAWJO-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- KJLDHYBSPPDMKK-UHFFFAOYSA-N 6-[(2-chlorophenyl)carbamoyl]-3,4-dimethylcyclohex-3-ene-1-carboxylic acid Chemical compound OC(=O)C1CC(C)=C(C)CC1C(=O)NC1=CC=CC=C1Cl KJLDHYBSPPDMKK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 101100452593 Caenorhabditis elegans ina-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 101100388057 Mus musculus Poln gene Proteins 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000429017 Pectis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000141 anti-hypoxic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004600 colonic motility Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- KOWWOODYPWDWOJ-LVBPXUMQSA-N elatine Chemical compound C([C@]12CN(C3[C@@]45OCO[C@]44[C@H]6[C@@H](OC)[C@@H]([C@H](C4)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]5OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O KOWWOODYPWDWOJ-LVBPXUMQSA-N 0.000 description 1
- MKHLSGKJYGBQLI-UHFFFAOYSA-N ethoxy-(2-ethylsulfanylethylsulfanyl)-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound CCOP(=S)(OC)SCCSCC MKHLSGKJYGBQLI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58104873A JPS59231057A (ja) | 1983-06-14 | 1983-06-14 | カルボン酸アミド化合物およびその誘導体 |
| JP104,873/83 | 1983-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1215992A true CA1215992A (en) | 1986-12-30 |
Family
ID=14392332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000456279A Expired CA1215992A (en) | 1983-06-14 | 1984-06-11 | Carboxylic acid amide compounds and their derivatives |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4596826A (en, 2012) |
| JP (1) | JPS59231057A (en, 2012) |
| KR (1) | KR850001153A (en, 2012) |
| AU (1) | AU582117B2 (en, 2012) |
| BE (1) | BE899918A (en, 2012) |
| CA (1) | CA1215992A (en, 2012) |
| CH (1) | CH659243A5 (en, 2012) |
| DE (1) | DE3421929A1 (en, 2012) |
| DK (1) | DK289684A (en, 2012) |
| ES (2) | ES533372A0 (en, 2012) |
| FR (1) | FR2548180B1 (en, 2012) |
| GB (1) | GB2141713B (en, 2012) |
| HU (1) | HU191674B (en, 2012) |
| IT (1) | IT1180188B (en, 2012) |
| NL (1) | NL8401890A (en, 2012) |
| PH (2) | PH20503A (en, 2012) |
| SE (1) | SE8403168L (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59118750A (ja) * | 1982-12-27 | 1984-07-09 | Eisai Co Ltd | カルボン酸アミド化合物およびその誘導体 |
| EP0302934A4 (en) * | 1987-02-26 | 1990-12-12 | Nippon Zeon Co., Ltd. | Alicyclic dicarboxylic acid derivatives and muscle relaxants containing them as effective ingredients |
| JP4663748B2 (ja) * | 2008-03-10 | 2011-04-06 | 三菱重工交通機器エンジニアリング株式会社 | ボーディングブリッジの接続部およびボーディングブリッジ |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2774787A (en) * | 1953-09-03 | 1956-12-18 | Charles F Geschickter | Polyhydrophthalamic acid visceral smooth muscle relaxants |
| US3131509A (en) * | 1961-05-08 | 1964-05-05 | Spencer Chem Co | Compositions and methods for reducing herbicidal injury |
| US3507904A (en) * | 1966-04-01 | 1970-04-21 | Herbert Schwartz | Novel tetrahydrophthalamic acids and derivatives thereof |
| US3745170A (en) * | 1969-03-19 | 1973-07-10 | Sumitomo Chemical Co | Novel n-(3,5-dihalophenyl)-imide compounds |
| US3654302A (en) * | 1970-01-30 | 1972-04-04 | Herbert Schwartz | Tetrahydrophthalanils |
| JPS4882038A (en, 2012) * | 1972-02-08 | 1973-11-02 | ||
| US3987056A (en) * | 1973-05-07 | 1976-10-19 | Phillips Petroleum Company | Disproportionation of n-aryl-1,2,3,6-tetrahydrophthalimides |
| US4002460A (en) * | 1974-03-13 | 1977-01-11 | Stauffer Chemical Company | Triazine-antidote compositions and methods of use for cotton |
| US3996043A (en) * | 1975-04-10 | 1976-12-07 | Stauffer Chemical Company | Triazine--antidote compositions and methods of use for cotton |
| PT71116A (de) * | 1979-04-20 | 1980-05-01 | Ciba Geigy Ag | Verfahren zur herstellung neuer cyclobutandicarbonsaureimide |
| JPS56169669A (en) * | 1980-05-30 | 1981-12-26 | Takeda Chem Ind Ltd | Hexahydroisoindole derivative, its preparation and herbicide |
| JPS59118750A (ja) * | 1982-12-27 | 1984-07-09 | Eisai Co Ltd | カルボン酸アミド化合物およびその誘導体 |
-
1983
- 1983-06-14 JP JP58104873A patent/JPS59231057A/ja active Granted
-
1984
- 1984-06-11 PH PH30801A patent/PH20503A/en unknown
- 1984-06-11 CA CA000456279A patent/CA1215992A/en not_active Expired
- 1984-06-12 US US06/620,050 patent/US4596826A/en not_active Expired - Fee Related
- 1984-06-13 IT IT21378/84A patent/IT1180188B/it active
- 1984-06-13 SE SE8403168A patent/SE8403168L/xx not_active Application Discontinuation
- 1984-06-13 DE DE19843421929 patent/DE3421929A1/de not_active Withdrawn
- 1984-06-13 ES ES533372A patent/ES533372A0/es active Granted
- 1984-06-13 DK DK289684A patent/DK289684A/da not_active Application Discontinuation
- 1984-06-13 HU HU842278A patent/HU191674B/hu not_active IP Right Cessation
- 1984-06-14 FR FR8409341A patent/FR2548180B1/fr not_active Expired
- 1984-06-14 KR KR1019840003332A patent/KR850001153A/ko not_active Ceased
- 1984-06-14 BE BE0/213145A patent/BE899918A/fr not_active IP Right Cessation
- 1984-06-14 CH CH2883/84A patent/CH659243A5/de not_active IP Right Cessation
- 1984-06-14 NL NL8401890A patent/NL8401890A/nl not_active Application Discontinuation
- 1984-06-14 AU AU29379/84A patent/AU582117B2/en not_active Ceased
- 1984-06-14 GB GB08415153A patent/GB2141713B/en not_active Expired
-
1985
- 1985-07-16 ES ES545252A patent/ES8603824A1/es not_active Expired
- 1985-12-12 PH PH33166A patent/PH21315A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE8403168L (sv) | 1984-12-15 |
| CH659243A5 (de) | 1987-01-15 |
| ES8603383A1 (es) | 1985-12-16 |
| PH20503A (en) | 1987-01-21 |
| DE3421929A1 (de) | 1984-12-20 |
| ES533372A0 (es) | 1985-12-16 |
| BE899918A (fr) | 1984-12-14 |
| SE8403168D0 (sv) | 1984-06-13 |
| DK289684A (da) | 1984-12-15 |
| AU582117B2 (en) | 1989-03-16 |
| ES545252A0 (es) | 1986-01-01 |
| US4596826A (en) | 1986-06-24 |
| GB8415153D0 (en) | 1984-07-18 |
| PH21315A (en) | 1987-09-28 |
| HU191674B (en) | 1987-03-30 |
| IT8421378A1 (it) | 1985-12-13 |
| GB2141713A (en) | 1985-01-03 |
| DK289684D0 (da) | 1984-06-13 |
| KR850001153A (ko) | 1985-03-16 |
| AU2937984A (en) | 1984-12-20 |
| HUT36084A (en) | 1985-08-28 |
| GB2141713B (en) | 1987-06-10 |
| JPH0136820B2 (en, 2012) | 1989-08-02 |
| NL8401890A (nl) | 1985-01-02 |
| JPS59231057A (ja) | 1984-12-25 |
| FR2548180A1 (fr) | 1985-01-04 |
| IT1180188B (it) | 1987-09-23 |
| IT8421378A0 (it) | 1984-06-13 |
| ES8603824A1 (es) | 1986-01-01 |
| FR2548180B1 (fr) | 1987-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4260769A (en) | 5,5-Diphenylhydantoins | |
| JPS62161728A (ja) | 抗菌剤 | |
| JPH01246265A (ja) | ４‐ピリドン‐３‐カルボン酸誘導体 | |
| CA2159546A1 (en) | Cycloalkano-indole and -azaindole derivatives | |
| US11780841B2 (en) | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same | |
| US3862139A (en) | Heterocyclic benzamide compounds | |
| US3856957A (en) | Methods and compositions for treating bacterial infections employing imines | |
| US4639454A (en) | Phenylquinazolinecarboxylic acids and derivatives as cancer chemotherapeutic agents | |
| US4163058A (en) | Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof | |
| CA1102345A (en) | Soft anticholinergic agents exhibiting anti-secretory activity | |
| KR900006722B1 (ko) | 항불안제 | |
| CA1215992A (en) | Carboxylic acid amide compounds and their derivatives | |
| WO2003000681A1 (fr) | Compose antibacterien comprenant un squelette quinolinecarboxamide | |
| US4189581A (en) | 2-Acylamino-4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidines | |
| GB1581593A (en) | Benzenesulphonyl ureas and process for preparing them | |
| UA6841A1 (uk) | Спосіб одержання похідних пірідазінона або їх водорозчинних солей з фармацевтично прийнятною кислотою | |
| US3845071A (en) | Imidazo(1,2-a)azacycloalkanes | |
| GB1411701A (en) | Compositions containing compounds of the eburnane structure | |
| JPS6089480A (ja) | ピリドンカルボン酸誘導体 | |
| US3790594A (en) | Thienyl-imidazolyl alkanoic acids | |
| US3635966A (en) | 6-substituted-indolo(1 2-c)quinazolines | |
| GB1319489A (en) | Tetrahydrocyclopropadibenzapine derivatives | |
| US3528968A (en) | Heterocyclic substituted imidazoline hydrazones | |
| US3817998A (en) | 2-amino and substituted amino-4, 6-diamino-5-pyrimidinesulfonamides | |
| JPS6028978A (ja) | １，８−ナフチリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |